Raport de activitate al Agenţiei Naţionale a Medicamentului şi a Dispozitivelor Medicale pentru anul 2017 Introducere Agenţi
REZUMATUL CARACTERISTICILOR PRODUSULUI 1. DENUMIREA COMERCIALĂ A MEDICAMENTULUI Borenar 2,5 mg/ml soluţie orală 2. COMPOZIŢ
![PDF) Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency PDF) Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency](https://i1.rgstatic.net/publication/250924403_Evaluation_of_the_Single-dose_Pharmacokinetics_of_Bilastine_in_Subjects_with_Various_Degrees_of_Renal_Insufficiency/links/02e7e526f6f287580d000000/largepreview.png)
PDF) Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
Raport de activitate al Agenţiei Naţionale a Medicamentului şi a Dispozitivelor Medicale pentru anul 2017 Introducere Agenţi
The role of bilastine in treating paediatric patients with allergic rhinoconjunctivitis and urticaria
![PDF) Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency PDF) Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency](https://www.researchgate.net/profile/Ander-Sologuren/publication/250924403/figure/fig3/AS:667058731757574@1536050603478/Mean-plasma-concentration-time-profile-of-bilastine-Filled-circles-group-1-normal-GFR_Q320.jpg)